DrugCite
Search

RELAFEN

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Relafen Adverse Events Reported to the FDA Over Time

How are Relafen adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Relafen, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Relafen is flagged as the suspect drug causing the adverse event.

Most Common Relafen Adverse Events Reported to the FDA

What are the most common Relafen adverse events reported to the FDA?

Drug Ineffective
23 (3.67%)
Diarrhoea
12 (1.92%)
Nausea
12 (1.92%)
Medication Error
11 (1.76%)
Pain
10 (1.6%)
Dizziness
9 (1.44%)
Fatigue
9 (1.44%)
Myalgia
9 (1.44%)
Arthralgia
8 (1.28%)
Rash
8 (1.28%)
Dyspnoea
7 (1.12%)
Show More Show More
Vision Blurred
7 (1.12%)
Pruritus
6 (.96%)
Somnolence
6 (.96%)
Urticaria
6 (.96%)
Asthenia
5 (.8%)
Condition Aggravated
5 (.8%)
Drug Hypersensitivity
5 (.8%)
Gait Disturbance
5 (.8%)
Malaise
5 (.8%)
Overdose
5 (.8%)
Rhabdomyolysis
5 (.8%)
Stevens-johnson Syndrome
5 (.8%)
Abdominal Pain
4 (.64%)
Abdominal Pain Upper
4 (.64%)
Back Pain
4 (.64%)
Blood Creatine Phosphokinase Increa...
4 (.64%)
Depression
4 (.64%)
Drug Dispensing Error
4 (.64%)
Dry Mouth
4 (.64%)
Dyspepsia
4 (.64%)
Dysphagia
4 (.64%)
Flatulence
4 (.64%)
Haematemesis
4 (.64%)
Hypersensitivity
4 (.64%)
Hypoaesthesia
4 (.64%)
Ill-defined Disorder
4 (.64%)
Injury
4 (.64%)
Joint Stiffness
4 (.64%)
Lethargy
4 (.64%)
Neck Pain
4 (.64%)
Oedema Peripheral
4 (.64%)
Photosensitivity Reaction
4 (.64%)
Rash Macular
4 (.64%)
Retinal Tear
4 (.64%)
Tremor
4 (.64%)
Visual Acuity Reduced
4 (.64%)
Anorexia
3 (.48%)
Blood Pressure Increased
3 (.48%)
Blood Testosterone Decreased
3 (.48%)
Contusion
3 (.48%)
Deafness
3 (.48%)
Dehydration
3 (.48%)
Drug Interaction
3 (.48%)
Drug Intolerance
3 (.48%)
Dry Eye
3 (.48%)
Gastric Disorder
3 (.48%)
Hip Arthroplasty
3 (.48%)
Hyperhidrosis
3 (.48%)
Intentional Drug Misuse
3 (.48%)
Irritability
3 (.48%)
Mouth Ulceration
3 (.48%)
Myocardial Infarction
3 (.48%)
Paraesthesia
3 (.48%)
Pneumonia
3 (.48%)
Pyrexia
3 (.48%)
Renal Failure
3 (.48%)
Swelling
3 (.48%)
Swelling Face
3 (.48%)
Tinnitus
3 (.48%)
Vomiting
3 (.48%)
Weight Decreased
3 (.48%)
Abasia
2 (.32%)
Abdominal Discomfort
2 (.32%)
Agitation
2 (.32%)
Alopecia
2 (.32%)
Anxiety
2 (.32%)
Balance Disorder
2 (.32%)
Blindness
2 (.32%)
Blister
2 (.32%)
Blood Creatinine Increased
2 (.32%)
Burning Sensation
2 (.32%)
Cardiac Failure Congestive
2 (.32%)
Cerebrovascular Accident
2 (.32%)
Chest Discomfort
2 (.32%)
Chronic Obstructive Pulmonary Disea...
2 (.32%)
Coronary Arterial Stent Insertion
2 (.32%)
Crying
2 (.32%)
Diabetes Mellitus
2 (.32%)
Drug Detoxification
2 (.32%)
Drug Effect Decreased
2 (.32%)
Drug Screen False Positive
2 (.32%)
Dysstasia
2 (.32%)
Eosinophilic Pneumonia
2 (.32%)
Eye Pain
2 (.32%)
Fluid Retention
2 (.32%)
Flushing
2 (.32%)
Gamma-glutamyltransferase Increased
2 (.32%)
Gastric Haemorrhage
2 (.32%)
Gingival Abscess
2 (.32%)
Headache
2 (.32%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Relafen, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Relafen is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Relafen

What are the most common Relafen adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Relafen, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Relafen is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Relafen According to Those Reporting Adverse Events

Why are people taking Relafen, according to those reporting adverse events to the FDA?

Rheumatoid Arthritis
76
Arthritis
73
Pain
70
Product Used For Unknown Indication
60
Drug Use For Unknown Indication
57
Osteoarthritis
38
Show More Show More
Arthralgia
34
Back Pain
22
Ill-defined Disorder
10
Fibromyalgia
9
Pain In Extremity
8
Inflammation
8
Antiinflammatory Therapy
5
Tendonitis
5
Psoriatic Arthropathy
4
Neck Injury
4
Neck Pain
4
Back Disorder
3
Intervertebral Disc Degeneration
3
Gout
3
Back Injury
3
Systemic Lupus Erythematosus
2
Bone Pain
2
Migraine
2
Carpal Tunnel Syndrome
2
Myalgia
2
Osteomyelitis
1
Shoulder Operation
1
Headache
1
Inflammatory Pain
1
Spinal Osteoarthritis
1
Juvenile Arthritis
1
Swelling
1
Joint Injury
1
Suicide Attempt
1
Spondyloarthropathy
1
Musculoskeletal Pain
1
Antiallergic Therapy
1
Limb Discomfort
1
Ankylosing Spondylitis
1
Musculoskeletal Chest Pain
1
Spinal Column Stenosis
1
Neuritis
1
Joint Sprain
1
Intervertebral Disc Protrusion
1
Mortons Neuroma
1
Costochondritis
1

Relafen Case Reports

What Relafen safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Relafen. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Relafen.